Susan M Ott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9173937/publications.pdf Version: 2024-02-01



SUSAN Μ ΟΤΤ

#	Article	IF	CITATIONS
1	Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee. Journal of Bone and Mineral Research, 1987, 2, 595-610.	2.8	4,558
2	Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, The, 1996, 348, 1535-1541.	13.7	3,496
3	Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research, 2013, 28, 2-17.	2.8	2,023
4	Incidence of atypical nontraumatic diaphyseal fractures of the femur. Journal of Bone and Mineral Research, 2012, 27, 2544-2550.	2.8	370
5	The Prevalence of Bone Aluminum Deposition in Renal Osteodystrophy and Its Relation to the Response to Calcitriol Therapy. New England Journal of Medicine, 1982, 307, 709-713.	27.0	352
6	Cortical or Trabecular Bone: What's the Difference?. American Journal of Nephrology, 2018, 47, 373-375.	3.1	135
7	Mineral Changes in Osteoporosis. Clinical Orthopaedics and Related Research, 2006, 443, 28-38.	1.5	127
8	Bone Mineral, Histomorphometry, and Body Composition in Adults with Growth Hormone Receptor Deficiency. Journal of Bone and Mineral Research, 1998, 13, 415-421.	2.8	102
9	Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women. Journal of Bone and Mineral Research, 2002, 17, 341-348.	2.8	97
10	Bone Structure in Patients with Low Bone Mineral Density With or Without Vertebral Fractures. Journal of Bone and Mineral Research, 2000, 15, 1368-1375.	2.8	93
11	When bone mass fails to predict bone failure. Calcified Tissue International, 1993, 53, S7-S13.	3.1	87
12	Cystatinâ€C, Renal Function, and Incidence of Hip Fracture in Postmenopausal Women. Journal of the American Geriatrics Society, 2008, 56, 1434-1441.	2.6	70
13	Histomorphometric Measurements of Bone Turnover, Mineralization, and Volume. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S151-S156.	4.5	57
14	What is the optimal duration of bisphosphonate therapy?. Cleveland Clinic Journal of Medicine, 2011, 78, 619-630.	1.3	52
15	Therapy for patients with CKD and low bone mineral density. Nature Reviews Nephrology, 2013, 9, 681-692.	9.6	34
16	Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD. Kidney International, 2014, 85, 1283-1289.	5.2	28
17	Bone strength: more than just bone density. Kidney International, 2016, 89, 16-19.	5.2	27
18	Journal of Bone and Mineral Research. Journal of Bone and Mineral Research, 1993, 8, S597-S606.	2.8	26

SUSAN M OTT

#	Article	IF	CITATIONS
19	Bisphosphonate safety and efficacy in chronic kidney disease. Kidney International, 2012, 82, 833-835.	5.2	26
20	Dâ€Lactate and Metabolic Bone Disease in Patients Receiving Longâ€Term Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 1989, 13, 132-135.	2.6	25
21	Journal of Bone and Mineral Research. Journal of Bone and Mineral Research, 1991, 6, S71-S76.	2.8	25
22	Histomorphometric Analysis of Bone Remodeling. , 2002, , 303-319.		20
23	Bone disease in CKD. Current Opinion in Nephrology and Hypertension, 2012, 21, 376-381.	2.0	15
24	Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease. Seminars in Dialysis, 2015, 28, 363-369.	1.3	15
25	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 1784-1802.	2.0	14
26	Renal Osteodystrophy—Time for Common Nomenclature. Current Osteoporosis Reports, 2017, 15, 187-193.	3.6	12
27	Bones and the sex hormones. Kidney International, 2018, 94, 239-242.	5.2	12
28	Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. JAMA Network Open, 2020, 3, e2025190.	5.9	12
29	Navel Jewelry Artifacts and Intravertebral Variation in Spine Bone Densitometry in Adolescents and Young Women. Journal of Clinical Densitometry, 2009, 12, 84-88.	1.2	11
30	Bone cells, sclerostin, and FGF23: what's bred in the bone will come out in the flesh. Kidney International, 2015, 87, 499-501.	5.2	11
31	Role of proton receptor OGR1 in bone response to metabolic acidosis?. Kidney International, 2016, 89, 529-531.	5.2	11
32	Bone formation periods studied with triple tetracycline labels in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research, 1993, 8, 443-450.	2.8	10
33	Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney International, 2021, 100, 502-505.	5.2	10
34	Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskeletal Disorders, 2020, 21, 801.	1.9	6
35	A comparison of self-reported oral contraceptive use and automated pharmacy data in perimenopausal and early postmenopausal women. Annals of Epidemiology, 2015, 25, 55-59.	1.9	5
36	Long-term bisphosphonates: primum non nocere. Menopause, 2016, 23, 1159-1161.	2.0	4

SUSAN M OTT

#	Article	IF	CITATIONS
37	What Are the Most Common Errors in the Management of Renal Osteodystrophy?. Seminars in Dialysis, 1989, 2, 145-146.	1.3	3
38	Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 719-723.	0.9	3
39	Renal insufficiency and bone loss. Current Opinion in Rheumatology, 2019, 31, 394-399.	4.3	2
40	Letter re: Alendronate in Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5508-5508.	3.6	2
41	Consider the Bisphosphonate Dose. Journal of Bone and Mineral Research, 2020, 37, 1-2.	2.8	2
42	Does Estrogen Play a Role in Renal Osteodystrophy?. Seminars in Dialysis, 1995, 8, 4-11.	1.3	1
43	Debating the duration of bisphosphonate therapy. JAAPA: Official Journal of the American Academy of Physician Assistants, 2013, 26, 64-65.	0.3	1
44	Osteoporosis Associated with Chronic Kidney Disease. , 2013, , 1387-1424.		1
45	Determinants of Oral Bisphosphonate Use Beyond 5 Years. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 197-202.	0.9	1
46	Osteoporosis associated with chronic kidney disease. , 2021, , 1325-1380.		1
47	Structural and Metabolic Assessment of Bone. Handbook of Experimental Pharmacology, 2020, 262, 369-396.	1.8	Ο
48	Not etched in bone: the role of osteoclast proton-sensing receptors. Kidney International, 2021, 99, 542-545.	5.2	0
49	Renal Osteodystrophy and Bone Biopsy. Nephrology Self-assessment Program: NephSAP, 2020, 19, 215-225.	3.0	0